Trading update

Immunodiagnostic Systems Holdings plc

Trading Update

Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of specialist diagnostic testing kits for the clinical and research markets, provides a trading update for the financial year ending 31 March 2011.

Turnover for the year ending 31 March 2011 is expected to be £50.1m, circa 35% ahead of last year's performance (FY10: £37.2m) with trading in all of the Company's main territories having increased year on year. Sales of both manual vitamin D and automated products have increased compared to last year.

Revenues from our manual Vitamin D kits increased by 27% to £27.9m compared to same period last year (FY10: £22m).

We are also pleased to report that sales and placements of the IDS-iSYS system have continued to increase and in the second half of the year, as we have sold and or placed another 101 instruments bringing the total number post launch to 241.

Number of IDS-iSYS instruments sold and placed post launch:

Average revenue per instrument from our own reagent rental accounts was ahead of management expectations at £102,000, circa 32% ahead of last year's performance (FY10: £77,000).

IDS-iSYS revenues accounted for circa 21% of total turnover, with sales in H2 of £7.0m compared to £3.3m in H1. Comparative sales in the previous year were H2: £2.1m and H1 £0.6m.

During the period the Company signed an exclusive Agreement with Omega Diagnostics Group PLC giving them the exclusive rights to develop and distribute their range of allergy products on the IDS-iSYS. In return IDS receives a licence fee, a royalty on Omega automated product sales and revenues from both instrument and consumable sales.

Balance Sheet

The Company has been asked to consider a renegotiation of the timing of payment of the deferred consideration receivable (€3.4m) in respect of the disposal in December 2008 of its Haematology Division. As of today's date there has been no provision made against this amount in the Company's Accounts. The position is being reviewed by the Board in light of this request.

Outlook

We look forward to reporting our results for the financial year ended 31 March 2011 on Monday 27 June 2011 and continue to look forward to the current year with confidence.

IDS will host a conference call for analysts at 8.30am today for further details please contact Walbrook PR (contact details below).

For further information: